Alcohol and small intestinal permeability

Alcohol and the Gastrointestinal Tract

Volumn , Issue , 2017, Pages 219-234

  Bjarnason, Ingvar ^a   Macpherson, Andrew ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 7144239567     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4324/9781315149844     Document Type: Chapter

References (152)

1. Menzies, I. S., Absorption of intact oligosaccharide in health and disease, Biochem. Soc. Trans., 2, 1040, 1974.
2. Chadwick, V. S., Phillips, S. F., and Hofman, A. F., Measurements of intestinal permeability using low molecular weight polyethylene glycols (PEG 400). I. Chemical analysis and biological properties of PEG 400, Gastroenterology, 73, 241, 1977.
3. Chadwick, V. S., Phillips, S. F., and Hofman, A. F., Measurements of intestinal permeability using low molecular weight polyethylene glycols (PEG 400). II. Application to study of normal and abnormal permeability states in humans and animals. Gastroenterology, 73, 247, 1977.
4. Bjarnason, I., Macpherson, A. J. M., and Hollander, D., Intestinal permeability: an overview, Gastroenterology, 108, 1566, 1995.
5. Laker, M. F. and Menzies, I. S., Increase in human intestinal permeability following ingestion of hypertonic solutions, J. Physiol. (Lond.), 273, 881, 1977.
6. Laker, M. F., The effect of hypertonic solutions on intestinal permeability, MD Thesis, University of London, 1978.
7. Wheeler, P. G., Menzies, I. S., and Creamer, B., Effect of hyperosmolar stimuli and coeliac disease on the permeability of the human gastrointestinal tract, Clin. Sci. Mol. Med., 54, 495, 1978.
8. Bjarnason, I., Peters, T. J., and Levi, A. J., Intestinal permeability: clinical correlates, Dig. Dis. Sci., 4, 83, 1986.
9. Hamilton, I., Small intestinal permeability, in Recent Advances in Gastroenterology, Vol. 6, Pounder, R. E., Ed., Churchill Livingstone, Edinburgh, 1986, 73.
10. Cooper, B. T., The small intestinal permeability barrier, in Gut Defenses in Clinical Practice, Losowski, M. H. and Heatley, R. V., Eds., Churchill Livingstone, Edinburgh, 1986, 117.
11. Menzies, I. S., Transmucosal passage of inert molecules in health and disease, in Intestinal Absorption and Secretion, Skadhauge, E. and Heintze, K., Eds., Falk Symposium 36, MTP Press, 1984, 527.
12. Hollander, D., The intestinal permeability barrier. A hypothesis as to its regulation and involvement in Crohn’s disease, Scand. J. Gastroenterol., 27, 721, 1992.
13. Hollander, D., Permeability in Crohn’s disease-altered barrier function in healthy relatives?. Gastroenterology, 104, 1848, 1993.
14. Maxton, D. G., Bjarnason, I., Reynolds, A. P., Catt, S. D., Peters, T. J., and Menzies, I. S., Lactulose, 51CrEDTA, L-rhamnose and polyethylene glycol 400 as probe markers for “in vivo" assessment of human intestinal permeability, Clin. Sci., 71, 71, 1986.
15. Laker, M. F., Bull, H. J., and Menzies, I. S., Evaluation of mannitol for use as a probe marker of gastrointestinal permeability in humans, Eur. J. Clin. Invest., 12, 485, 1982.
16. Cobden, I., Hamilton, I., Rothwell, J., and Axon, A. T. R., Cellobiose/mannitol test: physiological properties of probe molecules and influence of extraneous factors, Clin. Chim. Acta, 148, 53, 1985.
17. Dominguez, R., Corcoran, A. C., and Page, I. H., Mannitol: kinetics of distribution, excretion and utilization in human beings, J. Lab. Clin. Med., 32, 192, 1947.
18. Newman, E. V., Itordlav, J., and Winternitz, J., The interrelationship of glomerular filtration rate (mannitol clearance), extracellular fluid volume, surface area of the body, and plasma concentration of mannitol, Bull. Johns Hopkins Hosp., 75, 253, 1944.
19. 5lCr-labelled EDTA absorption test, Lancet, i, 323, 1983.
20. 5lCr EDTA in inflammatory bowel disease, Gastroenterology, 85, 318, 1983.
21. Bjarnason, I., Williams, P., So, A., Zanelli, G., Levi, A. J., Gumpel, M. J., Peters, T. J., and Ansell, B., Intestinal permeability and inflammation in rheumatoid arthritis; effects of non-steroidal anti-inflammatory drugs, Lancet, ii, 1171, 1984.
22. Bjarnason, I., Ward, K., and Peters, T. J., The leaky gut of alcoholism: possible route of entry for toxic compounds, Lancet, i, 179, 1984.
23. Bjarnason, I., Goolamali, S. K., Levi, A. J., and Peters, T. J., Intestinal permeability in patients with atopic eczema, Br. J. Dermatol., 112, 291, 1985.
24. Bjarnason, I. and Peters, T. J., Helping the mucosa make sense of macromolecules, Gut, 28, 1057, 1987.
25. Hamilton, I., Fairris, G. M., Rothwell, J., Cunliffe, W. J., Dixon, M. F., and Axon, A. T. R., Small intestinal permeability in dermatological disease, Q. J. Med., 56, 559, 1985.
26. Judby, L. D., Rothwell, J., and Axon, A. T. R., Lactulose/mannitol test. An ideal screening test for coeliac disease, Gastroenterology, 96, 79, 1989.
27. Magnusson, M., Magnusson, K. E., Sundqvist, T., and Dennebergz, T., Reduced intestinal permeability measured by differently sized polyethylene glycols in acute uremic rats, Nephron, 60, 193, 1992.
28. Magnusson, K. E. and Sundquist, T., Mathematical modelling for determining intestinal permeability using polyethylene glycol, Gut, 25, 428, 1983.
29. Magnusson, K. E., Sundquist, T., Sjodahl, R., and Tageson, C., Altered intestinal permeability to low-molecular-weight polyethylene glycols (PEG 400) in patients with Crohn’s disease, Acta Chir. Scand., 149, 323, 1983.
30. Magnusson, K. E. and Sundqvist, T., Modelling of intestinal permeability in humans to polyethylene glycols (PEG 400 and PEG 1000), Acta Physiol. Scand., 125, 289, 1985.
31. Magnusson, M., Magnusson, K. E., Sundqvist, T., and Denneberg, T., Urinary excretion of differently sized polyethylene glycols after intravenous administration in uremic and control rats: effects of low- and high-protein diets, Nephron, 56, 312, 1990.
32. Magnusson, M., Magnusson, K. E., Sundqvist, T., and Denneberg, T., Increased intestinal permeability to differently sized polyethylene glycols in uremic rats: effects of low- and high-protein diets, Nephron, 56, 306, 1990.
33. Sundquist, T., Magnusson, K. E., Sjodahl, R., Stjernstrom, I., and Tageson, C., Passage of molecules through the wall of the gastrointestinal tract. II. Application of low-molecular weight polyethyleneglycol and a deterministic mathematical model for determining intestinal permeability in humans, Gut, 21, 208, 1980.
34. Sundquist, T., Lindstrom, F., Magnusson, K. E., Skoldstram, L., Stjernstrom, I., and Tageson, C., Influence of fasting on intestinal permeability and disease activity in patients with rheumatoid arthritis, Scand. J. Rheumatol., 1 1, 33, 1982.
35. Sundquist, T., Magnusson, K. E., Larsson, L., Tageson, C., Hackman, L., and Nordenvall, B., Reduced intestinal permeability to low-molecular-weight polyethylene glycols (PEG400) in patients with jejunoileal bypass, Acta Chir. Scand., 150, 567, 1984.
36. Sundquist, T., Tageson, C., and Magnusson, K. E., Simulation of a multicompartment model for the intestinal permeability to low-molecular-weight probes (polyethylene glycol 400), Math. Biosci., 56, 287, 1981.
37. Tageson, C., Anderson, P. A., Anderson, J., Bolin, T., Kallberg, M., and Sjodahl, R., Passage of molecules through the wall of the gastrointestinal tract. Measurement of intestinal permeability to polyethylene glycols in the range 634-1338 dalton range (PEG 1000), Scand. J. Gastroenterol., 18, 481, 1983.
38. Tageson, C. and Bengtsson, A., Intestinal permeability to different sized polyethylene glycols in patients with rheumatoid arthritis, Scand. J. Rheumatol., 12, 124, 1983.
39. Hollander, D., Rickets, D., and Boyd, C. A. R., Importance of “probe” molecular geometry in determining intestinal permeability, Can. J. Gastroenterol, 2 (Suppl. A), 35A, 1988.
40. Ma, T. Y., Hollander, D., Krugliak, P., and Katz, K., PEG 400, a hydrophyllic molecular probe for measuring intestinal permeability, Gastroenterology, 98, 39, 1990.
41. Krugilak, P., Hollander, D., Ma, T. Y., Tran, D., Dadufalza, V. D., Katz, K. D., and Ce, K., Mechanism of polyethylene glycol 400 permeability of perfused rat intestine. Gastroenterology, 97, 1164, 1989.
42. Krugliak, P., Hollander, D., Le, K., Ma, T., Dadufalza, V. D., and Katz, K. D., Regulation of polyethylene glycol 400 intestinal permeability by endogenous and exogenous prostanoids. Influence of non-steroidal antiinflammatory drugs, Gut, 31, 417, 1990.
43. Iqbal, T. H., Lewis, K. O., and Cooper, B. T., Diffusion of polyethylene glycol-400 across lipid barriers in vitro, Clin. Sci., 85, 111, 1993.
44. Davin, J. C., Forget, P., and Mahieu, P. R., Increased intestinal permeability to (51Cr)EDTA is correlated with IgA immune complex-plasma levels in children with IgA-associated nephropathies, Acta Pediatr. Scand., 11, 118, 1988.
45. Ferry, D. M., Butt, T. J., Broom, M. F., Hunter, J., and Chadwick, V. S., Bacterial chemotactic oligopeptides and the intestinal mucosal barrier, Gastroenterology, 97, 61, 1989.
46. Ramage, J. K., Stanisz, A., Scicchitano, R., Hunt, R. H., and Perdue, M. H., Effects of immunologic reactions on rat intestinal epithelium. Correlation of increased intestinal permeability to chromium 51 labelled ethylenediaminetetraacetic acid and ovalbumin during acute inflammation and anaphylaxis, Gastroenterology, 94, 1368, 1988.
47. Irving, C. S., Lifschitz, C. H., Marks, L. M., Nichols, B. C., and Klein, P. D., Polyethylene glycol polymers of low molecular weight as probes of intestinal permeability. I. Innovations in analyses and quantitation, J. Lab. Clin. Med., 107, 290, 1986.
48. Menzies, I. S., Jenkins, A. P., Heduan, E., Catt, S. D., Segal, M. B., and Creamer, B., The effect of poorly absorbed solute on intestinal absorption, Scand. J. Gastroenterol., 25, 1257, 1990.
49. Bjarnason, I., Maxton, D., Reynolds, A. P., Catt, S., Peters, T. J., and Menzies, I. S., A comparison of 4 markers of intestinal permeability in control subjects and patients with coeliac disease, Scand. J. Gastroenterol., 26, 630, 1994.
50. Menzies, I. S., Pounder, R., Heyer, S., Laker, M. F., Bull, J., Wheeler, P. G., and Creamer, B., Abnormal intestinal permeability to sugars in villus atrophy, Lancet, ii, 1107, 1979.
51. l4C-mannitol methods for intestinal permeability, Scand. J. Gastroenterol., 28, 274, 1993.
52. 51Cr labelled ethylenediaminetetraacetate as markers of intestinal permeability in humans, Clin. Sci., 73, 197, 1987.
53. Andre, F., Andre, C., and Emery, Y., Assessement of the lactulose-mannitol test in Crohn’s disease, Gut, 29, 511, 1988.
54. Kapembwa, M. S., Fleming, S. C., Sewankambo, N., Serwadda, D., Lucas, S., Moody, A., and Griffin, G. E., Altered small-intestinal permeability associated with diarrhoea in human-immunodeficiency-virus-infected Caucasian and African subjects, Clin. Sci., 81, 327, 1991.
55. Murphy, M. S., Eastham, E. J., Nelson, R., Pearson, A. D. J., and Laker, M. F., Intestinal permeability in Crohn’s disease. Arch. Dis. Child., 64, 321, 1989.
56. Ukabam, S. O., Homeda, M. A., and Cooper, B. J., Small intestinal permeability in Sudanese subjects: evidence of tropical enteropathy, Trans. R. Soc. Trop. Med. Hyg., 40, 204, 1986.
57. van der Hulst, P. R. W. J., Kreel, B. K., Meyenfelt, M. F., Brummer, R.-J. M., Arends, J.-W., Deytz, N. E. P., and Soeters, P. B., Glutamine and the preservation of gut integrity, Lancet, 341, 1363, 1993.
58. Wyatt, J., Vogelsang, H., Hubl, W., Waldhoer, T., and Lochs, H., Intestinal permeability and the predictor of relapse in Crohn’s disease, Lancet, 341, 1437, 1993.
59. Sutherland, L. R., Verhoef, M., Wallace, J. L., Rosendaahl, G. V., Crutcher, R., and Meddings, J. B., A simple, non-invasive marker of gastric damage: sucrose permeability, Lancer, 343, 998, 1994.
60. 5lCr-ethylenediaminetetraacetic acid. A test to distinguish colonic from small-intestinal permeability change, Scand. J. Gastroenterol., 27, 769, 1992.
61. Jenkins, A. P., Trew, D. R., Crump, B. J., Menzies, I. S., and Creamer, B., Do nonsteroidal anti-inflammatory drugs increase colonic permeability?, Gut, 32, 66, 1991.
62. Qvist, H., Somasundaram, S., Macpherson, A., Menzies, I. S., Giercksky, K., and Bjarnason, I., The effect of pelvic radiation on small and large intestinal absorption and permeability in humans, Gastroenterology, 106, A430, 1994.
63. Teahon, K., Smith, T., Smethurst, P., and Bjarnason, I., A technique for localizing alterations of intestinal permeability in man, Gastroenterology, 100, A251, 1991.
64. Maxton, D. G., Catt, S. D., and Menzies, I. S., Intestinal disaccharidases assessed in congenital asucrasia by differential urinary disaccharide excretion, Dig. Dis. Sci., 34, 129, 1989.
65. Maxton, D. G., Catt, S. D., and Menzies, I. S., Combined assessment of intestinal disaccharidases in congenital asucrasia by differential urinary disaccharide excretion, J. Clin. Pathol., 43, 406, 1990.
66. Bjarnason, I., Smethurst, P., Batt, R., Catt, S., Maxton, D., and Menzies, I. S., Differential urine excretion of disaccharides for the non-invasive assessment of intestinal disaccharidase activities: effects of a-glucosidase inhibitors and primary hypolactasia, and the correlation between in vivo and in vitro measurements of sucrase, lactase and isomaltase activity in patients with coeliac disease, submitted, 1995.
67. Ford, R. P. K., Menzies, I. S., Phillips, A. D., Walker-Smith, J. A., and Turner, M. W., Intestinal sugar permeability: relationship to diarrheal disease and small bowel morphology, J. Pediatr. Gastroenterol. Nutr., 4, 568, 1985.
68. Walker, A. W. and Isselbacher, K. J., Uptake and transport of macromolecules by the intestine. Possible role in clinical disorders. Gastroenterology, 67, 531, 1974.
69. Walker, W. A., Mechanisms of antigen handling by the gut, Clin. Immunol. Allergy, 2, 15, 1982.
70. Sanderson, I. R. and Walker, W. A., Uptake and transport of macromolecules by the intestine: possible role in clinical disorders (an update), Gastroenterology, 104, 622, 1993.
71. Bjarnason, I., Macpherson, A., Somasundaram, S., and Teahon, K., Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease, Can. J. Gastroenterol., 7, 160, 1993.
72. Bjarnason, I., Macpherson, A. J. S., Somasundaram, S., and Teahon, K., Non-steroidal anti-inflammatory drugs and Crohn’s disease, in Inflammatory Bowel Diseases: Pathophysiology as Basis of Treatment, Scholmeric, J., Kruis, W., Goebbell, H., Hohenberger, W., and Gross, V., Eds., Falk Symposium No. 67, Kluwer Academic Publishers, Lancaster, 1993, 208.
73. Bjarnason, I., Hayllar, J., Macpherson, A. J., and Russell, A. S., Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine, Gastroenterology, 104, 1832, 1993.
74. Auer, I. O., Habscheid, W., Hiller, S., Gerhards, W., and Eilles, C., Nicht-steroidale antiphlogistika erhohen die darmpermeabilitat, Dtsch. Med. Wochenschr., 112, 1032, 1987.
75. Bjarnason, I., Williams, P., Smethurst, P., Peters, T. J., and Levi, A. J., The effect of NSAIDs and prostaglandins on the permeability of the human small intestine, Gut, 27, 1292, 1986.
76. Bjarnason, I., Smethurst, P., Clarke, P., Menzies, I. S., Levi, A. J., and Peters, T. J., Effect of prostaglandins on indomethacin induced increased intestinal permeability in humans, Scand. J. Gastroenterol., 29 (Suppl. 164), 97, 1989.
77. Bjarnason, I., Fehilly, B., Smethurst, P., Menzies, I. S., and Levi, A. J., The importance of local versus systemic effects of non-steroidal anti-inflammatory drugs to increase intestinal permeability in humans, Gut, 32, 275, 1991.
78. Bjarnason, I., Smethurst, P., Macpherson, A., Walker, F., McElnay, J. C., Passmore, A. P., and Menzies, I. S., Glucose and citrate reduce the permeability changes caused by indomethacin in humans, Gastroenterology, 102, 1546, 1992.
79. Bjarnason, I., Smethurst, P., Fenn, G. C., Lee, C. F., Menzies, I. S., and Levi, A. J., Misoprostol reduces indomethacin induced changes in human small intestinal permeability, Dig. Dis. Sci., 34, 407, 1989.
80. Jenkins, R. T., Rooney, P. J., Jones, D. B., Bienenstock, J., and Goodacre, R. L., Increased intestinal permeability in patients with rheumatoid arthritis. A side effect of nonsteroidal antiinflammatory drug therapy, Br. J. Rheumatol, 26, 103, 1987.
81. 5lCr-ethylenediaminetetraacetic acid absorption test. Effects of naproxen, a nonsteroidal, antiinflammatory drug, Scand. J. Gastroenterol, 25, 917, 1990.
82. Bjarnason, I., Smethurst, P., Menzies, I. S., and Peters, T. J., The effect of polyacrylic acid polymers (carbopol) on small intestinal function and permeability changes caused by indomethacin, Scand. J. Gastroenterol., 26, 685, 1991.
83. Davies, G. R. and Rampton, D. S., The pro-drug sulindac may reduce the risk of intestinal damage associated with the use of conventional non-steroidal anti-inflammatory drugs, Aliment Pharmacol Ther., 5, 593, 1991.
84. Aabakken, L., Larsen, S., and Osnes, K., Sucralfate for prevention of naproxen-induced mucosal lesions, Scand. J. Rheumatol, 18, 361, 1989.
85. Aabakken, L., Larsen, S., and Osnes, M., Cimetidine tablets or suspension in the prevention of gastrointestinal mucosal lesions caused by nonsteroidal anti-inflammatory drugs, Scand. J. Rheumatol, 18, 647, 1989.
86. Levine, R. A., Petokas, S., Nandi, J., and Enthoven, D., Effects of nonsteroidal anti-inflammatory drugs on gastrointestinal injury and prostanoid generation in healthy volunteers, Dig. Dis. Sci., 33, 660, 1988.
87. Ligumski, M., Golanska, E. M., Hansen, D. G., and Kauffman, G. L., Aspirin can inhibit gastric mucosal cyclo-oxygenase without causing lesions in the rat, Gastroenterology, 84, 756, 1983.
88. Rainsford, K. D., The biochemical pathology of aspirin induced gastric damage, Agents Actions, 5, 326, 1975.
89. Redfern, J. S. and Feldman, M., Role of prostaglandins in preventing gastrointestinal ulceration: induction of ulcers by antibodies to prostaglandins, Gastroenterology, 96, 596, 1989.
90. Whittle, B. J. R., Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and gastrointestinal damage induced by indomethacin in the rat, Gastroenterology, 80, 94, 1981.
91. Brune, K., Dietzel, K., Nürnberg, B., and Schneider, H.-Th., Recent insight into the mechanism of gastroinestinal tract ulceration, Scand. J. Rheumatol., 65 (Suppl.), 135, 1987.
92. Del Soldato, P., Foschi, D., Benoni, G., and Velo, G. P., Early and late phases in the formation by antiinflammatory drugs of intestinal lesions in the rat, in Side Effects of Antiinflammatory Drugs, Rainsford, K. D. and Velo, G. P., Eds., MTP Press, Lancaster, 1987, 67.
93. Duggan, D. E., Hooke, K. F., Noll, R. M., and Kwan, C. K., Enterohepatic circulation of indomethacin and its role in intestinal irritation, Biochem. Pharmacol., 25, 1749, 1975.
94. Fang, W.-F., Broughton, A., and Jacobson, E. D., Indomethacin-induced intestinal inflammation, Dig. Dis. Sci., 22, 187, 1977.
95. Kent, T. H., Cardeli, R. M., and Stanler, F. U., Small intestinal ulcers and intestinal flora in rats given indomethacin, Am. J. Pathol54, 237, 1969.
96. Melrange, R., Moore, G., Blower, P. R., Coates, M. E., Ward, F. W., and Ronaasen, V., A comparison of indomethacin with ibuprufen on gastrointestinal mucosal integrity in conventional and germ free rats, Aliment Pharmacol. Ther., 6, 67, 1992.
97. Robert, A. and Asano, T., Resistance of germ free rats to indomethacin-induced intestinal lesions, Prostaglandins, 14, 331, 1977.
98. Satoh, H., Guth, P. H., and Grossman, M. I., Role of bacteria in gastric ulceration produced by indomethacin in the rat: cytoprotective action of antibiotics, Gastroenterology, 84, 483, 1983.
99. Rainsford, K. D., Mucosal lesions induced in the rat intestinal tract by the anti-inflammatory drug, Wy-41,770, a weak inhibitor of prostaglandin synthesis, contrasted with those from the potent prostaglandin inhibitor, indomethecin, Toxicol. Pathol., 16, 366, 1988.
100. Bjarnason, I., Hayllar, J., Smethurst, P., Price, A. B., Menzies, I. S., and Gumpel, M. J., Metronidazole reduces inflammation and blood loss in NSA1D enteropathy, Gut, 33, 1204, 1992.
101. Teahon, K. and Bjarnason, I., Comparison of leukocyte excretion and blood loss in inflammatory disease of the bowel, Gut, 34, 1535, 1993.
102. Bjarnason, I., Zanelli, G., Smith, T., Prouse, P., Williams, P., DeLacey, G., Gumpel, M. J., and Levi, A. J., Nonsteroidal antiinflammatory drug induced intestinal inflammation in humans, Gastroenterology, 93,480, 1987.
103. Rooney, P. J., Jenkins, R. T., Smith, K. M., and Coates, G., 111-Indium-labelled polymorphonuclear scans in rheumatoid arthritis — an important clinical cause of positive results, Br. J. Rheumatol., 15, 167, 1986.
104. Segall, A. W., Isenberg, D. A., Hajirousow, V., Tolfree, S., Clark, J., and Snaith, M. L., Preliminary evidence for gut involvement in the pathogenesis of rheumatoid arthritis?, Br.1. Rheumatol., 25, 162, 1986.
105. Morris, A. J., Wasson, L. A., and Mackenzie, J. F., Small bowel enteroscopy in undiagnosed gastrointestinal blood loss. Gut, 33, 887, 1992.
106. Allison, M. C., Howatson, A. G., Torrance, C. J., Lee, F. D., and Russell, R. I., Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs, N. Engl. J. Med., 327, 749, 1992.
107. Bjarnason, I., Zanelli, G., Prouse, P., Smethurst, P., Levi, S., Gumpel, M. J., and Levi, A. J., Blood and protein loss via small intestinal inflammation induced by nonsteroidal anti-inflammatory drugs, Lancet, 2, 711, 1987.
108. Hayllar, J., Price, A. B., Smith, T., Macpherson, A., Gumpel, M. J., and Bjarnason, I., Nonsteroidal antiinflammatory drug-induced small intestinal inflammation and blood loss: effect of sulphasalazine and other disease modifying drugs, Arthritis Rheum., 37, 1146, 1994.
109. Bjarnason, I., Zanelli, G., Smethurst, P., Burke, M., Gumpel, M. J., Price, A. B., and Levi, A. J., Clinico-pathological features of nonsteroidal antiinflammatory drug induced small intestinal strictures, Gastroenterology, 94, 1070, 1988.
110. Lang, J., Price, A. B., Levi, A. J., Burk, M., Gumpel, J. M., and Bjarnason, I., Diaphragm disease: the pathology of non-steroidal anti-inflammatory drug induced small intestinal strictures, J. Clin. Pathol., 41, 516, 1988.
111. Halter, F., Weber, B., Huber, T., Eigenmann, F., Frey, M., and Rutchi, C., Diaphragm disease of the ascending colon associated with sustained release diclofenac, J. Clin. Gastroenterol., 16, 74, 1993.
112. Huber, T., Ruchti, C., and Halter, F., Nonsteroidal antiinflammatory drug-induced colonic strictures: a case report, Gastroenterology, 100, 1119, 1992.
113. Sheers, R. and Williams, W. R., NSAIDs and gut damage, Lancet, ii, 1154, 1989.
114. Fellows, I. W., Clarke, J. M., and Roberts, P. F., Non-steroidal anti-inflammatory drug-induced jejunal and colonic diaphragm disease: a report of two cases, Gut, 33, 1424, 1992.
115. Monahan, W., Starnes, E. C., and Parker, A. L., Colonic strictures in a patient on long-term non-steroidal antiinflammatory drugs, Gastrointest. Endosc., 38, 385, 1992.
116. Sturges, H. F. and Krone, C. L., Ulcers and strictures of the jejunum in a patient on long term indomethacin therapy, Am. J. Gastroenterol., 59, 162, 1973.
117. Neoptolemos, J. P. and Locke, T. J., Recurrent small bowel obstruction associated with phenylbutazone, Br. J. Surg., 70, 244, 1983.
118. Madhok, R., Mackenzie, J. A., Lee, F. D., Bruckner, F. E., Terry, T. R., and Sturrock, R. D., Small bowel ulceration in patients receiving NSAIDs for rheumatoid arthritis, Q. J. Med., 58, 53, 1986.
119. Saverymuttu, S. H., Thomas, A., Grundy, A., and Maxwell, J. D., Ileal stricturing after long term indomethacin treatment, Postgrad. Med. J., 62, 267, 1986.
120. Sukumar, L., Recurrent small bowel obstruction with piroxicam, Br. J. Surg., 74, 186, 1987.
121. Johnson, F., Recurrent small bowel obstruction with piroxicam, Br. J. Surg., 74, 654, 1987.
122. Budillon, G., Parrilli, G., Pacella, M., Cuomo, R., and Menzies, I. S., Investigation of intestine and liver function in cirrhosis using combined sugar oral loads, J. Hepatol., 1, 513, 1985.
123. Romiti, A., Merli, M., Martorano, M., Parilli, G., Martino, F., Riggio, O., Trucelli, A., Copocaccia L., and Budillion, G., Malabsorption and nutritional abnormalities in patients with liver cirrhosis, Ital. J. Gastroenterol., 22, 118, 1990.
124. Bac, D. J., Swart, R., van der Berg, J. W. O., and Wilson, J. H. P., Small bowel wall function in patients with advanced liver cirrhosis and portal hypertension: studies on permeability and luminal bacterial overgrowth, Eur. J. Gastroenterol. Hepatol., 5, 383, 1993.
125. Wicks, C., Somasundaram, S., Menzies, I. S., Bjarnason, I., and Williams, R., Intestinal function and postoperative enteral nutrition following liver transplants. Gut, 34 (Suppl. 1), S65, 1993.
126. Smethurst, P., Menzies, I. S., Levi, A. J., and Bjarnason, I., Is alcohol directly toxic to the small bowel mucosa?, Clin. Sci., 75, 50, 1988.
127. 5Cr ethylenediaminetetraacetic acid absorption test. Methodological aspects, Scand. J. Gastroenterol., 24, 351, 1989.
128. Robinson, G. M., Orrego, H., Israel, Y., Deveny, P., and Kapur, B. M., Low-molecular weight polyethylene glycol as a probe of gastrointestinal permeability after alcohol ingestion, Dig. Dis. Sci., 26, 23, 1981.
129. Worthington, B. S., Meserole, L., and Syrotuck, J. A., Effect of daily ethanol ingestion on intestinal permeability to macromolecules, Dig. Dis. Sci., 23, 23, 1978.
130. Bode, C., Vollmer, E., Hug, J., and Bode, J. C., Increased permeability of the gut to polyethylene glycol and dextran in rats fed alcohol, Ann. N.Y. Acad. Sci., 625, 837, 1991.
131. 51CrEDTA in rats with experimentally induced enteropathy, Gut, 26, 579, 1985.
132. Parrilli, G., Iaffaioli, R. V., Martorano, M., Cuomo, R., Tafuto, S., Zampino, M. G., Budillon, G., and Bianco, A. R., Effects of anthracycline therapy on intestinal absorption in patients with advanced breast cancer, Cancer Res., 49, 3689, 1989.
133. Pledger, J. V., Pearson, A. D. J., Craft, A. W., Laker, M. F., and Eastham, E. J., Intestinal permeability during chemotherapy for childhood tumors, Eur. J. Pediatr., 147, 123, 1988.
134. Pearson, A. D. J., Craft, A. W., Pledger, J. V., Eastham, E. J., Laker, M. F., and Pearson, C. S., Small bowel function in acute lymphoblastic leukemia, Arch. Dis. Child, 59, 460, 1984.
135. Selby, P. J., Lopes, N., Mundy, J., Crofts, M., Millar, J. L., and McElwain, T. J., Cyclophosphomide priming reduces intestinal damage in humans following high dose melphalan chemotherapy, Br. J. Cancer, 55, 531, 1987.
136. Cooper, B. T., Ukabam, S. O., O’Brien, I. A. D., Hara, J. P. O., and Corrall, R. J. M., Intestinal permeability in diabetic diarrhoea, Diabetic Med., 4, 49, 1987.
137. Ohri, S. K., Somasundaram, S., Koak, Y., Macpherson, A., Keogh, B. E., Taylor, K. M., Menzies, I. S., and Bjarnason, I., The effect of intestinal hypoperfusion during cardiopulmonary bypass surgery on saccharide permeation and intestinal permeability in humans, Gastroenterology, 106, 318, 1994.
138. Otamiri, T., Sjodahl, R., and Tagesson, C., An experimental model for studying reversible intestinal ischemia, Acta Chir. Scand., 153, 51, 1987.
139. Roumen, R. M., van der Vliet, J. A., Wevers, R. A., and Goris, R. J., Intestinal permeability is increased after major vascular surgery, J. Vase. Surg., 17, 734, 1993.
140. MC mannitol in humans, Int. J. Hyperthermia, 4, 467, 1988.
141. Ruppin, H., Hotze, A., During, A., Reichert, M., Bauer, J., Stoll, R., Herbst, M., and Mahlstedt, J., Reversible funktionsstorungen des intestinaltraktes durch abdominelle strahlentherapy, Z. Gastroenterol., 25, 261, 1987.
142. Yeoh, E. K., Horowitz, M., Russo, A., Muecke, T., Robb, T., and Chatterton, B. E., Gastrointestinal function in chronic radiation enteritis — effects of loperamide-N-oxide, Gut, 34, 476, 1993.
143. Kardossis, T., Joseph, A. E. A., Gane, J. N., and Bridges, C. E., Griffin, G. E., Fecal leucocytosis. Indium-111 labelled autologous polymorphonuclear leukocyte abdominal scanning, and quantitative fecal indium-111 excretion in acute gastroenteritis and enteropathogen carriage, Dig. Dis. Sci., 33, 1383, 1988.
144. 5 'CrEDTA in children with cystic fibrosis, J. Pediatr. Gastroenterol. Nutr., 5, 384, 1986.
145. Leclercq-Foucart, J., Forget, P., and Van Cutsem, J. L., Lactulose-rhamnose intestinal permeability in children with cystic fibrosis, J. Pediatr. Gastroenterol. Nutr., 6, 66, 1987.
146. Dalzell, A. M., Freestone, N. S., Billington, D., and Heaf, D. P., Small intestinal permeability and orocaecal transit time in cystic fibrosis, Arch. Dis. Child, 65, 585, 1990.
147. 5lCr-EDTA and orocecal transit time in cystic fibrosis, J. Pediatr. Gastroenterol. Nutr., 14, 204, 1992.
148. Pignata, C., Budillon, G., Monaco, G., Nani, E., Cuomo, R., Parrilli, G., and Ciccimarra, F., Jejunal bacterial overgrowth and intestinal permeability in children with immunodeficiency syndromes, Gut, 31, 879, 1990.
149. Teahon, K., Webster, A. D., Price, A. B., and Bjarnason, I., Studies of gastrointestinal structure and function in patients with primary hypogammaglobulinaemia, Gut, 35, 1244, 1994.
150. Keating, J., Bjarnason, I., Somasundaram, S., Macpherson, A., Francis, N., Price, A. B., Sharpstone, D., Smithson, J., Menzies, I. S., and Gazzard, I. S., Intestinal absorptive capacity, intestinal permeability and jejunal histology in HIV infected patients and their relation to diarrhea, Gut, in press, 1995.
151. Lim, S. G., Menzies, I. S., Lee, C. A., Johnson, M. A., and Pounder, R. E., Intestinal permeability and function in patients infected with human immunodeficiency virus, Scand. J. Gastroenterol., 28, 573, 1993.
152. Bjarnason, I., Somasundaram, S., MacManus, T., and Macpherson, A., Small intestinal permeability and inflammation in HIV infected patients, Gastroenterology, 104, A670, 1993.